TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17593235
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (0.4 U/kg)
Study: 2384192
Drug: 75-g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-g oral glucose tolerance test (OGTT)
Study: 2178521
Drug: Azelastine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 6 mg
Study: 2178521
Drug: Azelastine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine (all doses)
Study: 22281416
Drug: Flexible(MIB) regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible(MIB) regimen (ethinylestradiol 20 mcg/drospirenone 3 mg)
Study: 22281416
Drug: Flexible(APC) regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible(APC) regimen (ethinylestradiol 20 mcg/drospirenone 3 mg)
Study: 22281416
Drug: Conventional 24/4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 24/4 regimen (ethinylestradiol 20 mcg/drospirenone 3 mg)
Study: 20658805
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy only
Study: 15310939
Drug: Emtricitabine-containing treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine-containing treatment
Study: 15310939
Drug: Once-daily abacavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily abacavir regimens
Study: 15310939
Drug: Once-daily lopinavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily lopinavir/ritonavir regimens
Study: 15310939
Drug: Didanosine 400
Normalized name: didanosine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine 400 mg/tenofovir regimens
Study: 8553146
Drug: 1.8 mg
Normalized name: menthol 1.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg buserelin
Study: 8553146
Drug: 3.6 mg
Normalized name: menthol 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mg buserelin
Study: 8553146
Drug: 7.2 mg
Normalized name: lysine 7.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.2 mg buserelin
Study: 2700103
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg in a single morning dose
Study: 2700103
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg in a single nocte dose
Study: 28007635
Drug: Integrated pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Integrated pharmaceutical care at a psychosocial intervention
Study: 26653621
Drug: Renal artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal artery stent placement plus medical therapy
Study: 22207522
Drug: Dorzolamide/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide/timolol fixed combination (DTFC) (2 × 1) for 4 weeks
Study: 22207522
Drug: Brimonidine/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine/timolol fixed combination (BTFC) (2 × 1) for 4 weeks
Study: 19630975
Drug: Protocolized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized treatment based on active and passive joint repositioning, stabilization exercises, stretching of the periarticular shoulder muscles and postural reeducation.
Study: 19630975
Drug: Protocolized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized treatment with the addition of dry needling applied to active MTrPs.
Study: 16485577
Drug: Withholding levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding levothyroxine before 131I therapy (Group G1.1)
Study: 16485577
Drug: Withholding levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding levothyroxine before 131I therapy (Group G1.2)
Study: 16485577
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of recombinant human thyrotropin without stopping levothyroxine (Group G2)
Study: 15277271
Drug: BAY 38-3441
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 38-3441 at doses of 20, 40, 67, 100, 140, 210, 315, 470 and 600 mg/m2/day for 1 day every 3 weeks (single-dose schedule)
Study: 15277271
Drug: BAY 38-3441
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 38-3441 at doses of 126, 189, 246, 320 and 416 mg/m2/day once daily for three consecutive days every 3 weeks (3-day schedule)
Study: 11160951
Drug: Lamotrigine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (200 mg/day target maintenance dosage, adjusted from 100 to 500 mg/day)
Study: 11160951
Drug: Valproate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (20 mg/kg/day target maintenance dosage, adjusted from 10 to 60 mg/kg/day)
Study: 30519590
Drug: Fast administration
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast administration of 500ml balanced crystalloid fluid challenge (5-10 minutes)
Study: 30519590
Drug: Slow administration
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow administration of 500ml balanced crystalloid fluid challenge (20-30 minutes)
Study: 30519590
Drug: Fast administration
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast administration
Study: 30519590
Drug: Slow administration
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow administration
Study: 20831535
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg (RAC)
Study: 20831535
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg (EAC)
Study: 19024254
Drug: 1% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% CHX varnish applied once daily for 3 consecutive days (Group B)
Study: 19024254
Drug: Placebo varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo varnish applied once daily for 3 consecutive days (Group D)
Study: 16458191
Drug: High phenolic
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High phenolic content olive oil (366 mg/kg)
Study: 16458191
Drug: Moderate phenolic
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate phenolic content olive oil (164 mg/kg)
Study: 16458191
Drug: Low phenolic
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low phenolic content olive oil (2.7 mg/kg)
Study: 10573065
Drug: Basiliximab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (40 mg total: 20 mg on days 0 and 4)
Study: 9339962
Drug: H2 receptor
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 receptor antagonists, antacids, sucralfate, pirenzepine
Study: 3728212
Drug: Terbutaline (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (intravenous administration for 5 hours)
Study: 3728212
Drug: Isoprenaline (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprenaline (intravenous administration for 5 hours)
Study: 3728212
Drug: Terbutaline (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (oral administration for 24 days)
Study: 30834639
Drug: Neuromuscular blocking
Normalized name: Neuromuscular blocking agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular blocking agent first
Study: 30834639
Drug: Sedative agent
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative agent first
Study: 20140897
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g isomaltulose
Study: 20140897
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g sucrose
Study: 17650803
Drug: RT combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT combined with oral TCM from the start of RT till 5 weeks after RT
Study: 9430135
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (amino acid mixture containing 2.3 g of tryptophan)
Study: 7655769
Drug: Profinal (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profinal (600 mg)
Study: 7655769
Drug: Brufen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brufen (600 mg)
Study: 2571061
Drug: OM756 alpha
Normalized name: Alpha Arbutin
DrugBank: alpha-Arbutin (DB14109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM756 alpha 10 mg propranolol 'Inderal' tablet
Study: 2571061
Drug: Generic 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic 10 mg propranolol tablet
Study: 1099176
Drug: 4000 mg
Normalized name: talc 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 mg of ascorbic acid administered 27 and 3 hours prior to assessment
Study: 1099176
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of ascorbic acid administered in the same manner
Study: 23065145
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral tenofovir (TFV)
Study: 23065145
Drug: Daily topical
Normalized name: Clindagel 1 % Once-Daily Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily topical tenofovir (TFV) vaginal gel
Study: 23065145
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral tablet and vaginal gel
Study: 16449754
Drug: Cholinesterase inhibitor
Normalized name: Acetylcholinesterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitor treatment (AD+ChEI)
Study: 16449754
Drug: No Cholinesterase
Normalized name: cholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Cholinesterase inhibitor treatment (AD‐ChEI)
Study: 15339677
Drug: Adverse cytogenetics
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse cytogenetics and white blood cell count ≥20 yen 10^9/L at diagnosis
Study: 8187315
Drug: High insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High insulin infusion (60 mU/kg/h)
Study: 8187315
Drug: Low insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low insulin infusion (15 mU/kg/h)
Study: 8187315
Drug: Both insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both insulin levels
Study: 2835977
Drug: Diet 1
Normalized name: Phendiet 105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 1 (40% energy as carbohydrate, 10 g dietary fibre)
Study: 2835977
Drug: Diet 2
Normalized name: gluc-msm-vit C-FA-mang-diet 29 125 mg-37.5 mg-25 mg-500 mcg-1.25 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 2 (40% energy as carbohydrate, 52 g dietary fibre)
Study: 2835977
Drug: Diet 3
Normalized name: Phendiet 35 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 3 (60% energy as carbohydrate, 84 g dietary fibre)
Study: 24620666
Drug: Conventional symptomatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional symptomatic treatment
Study: 31568799
Drug: Oral maribavir
Normalized name: maribavir
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral maribavir treatment
Study: 31568799
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of F342Y and H411Y
Study: 23835011
Drug: Weekly friendly
Normalized name: Fisherman's Friend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly friendly visits (FV) (n = 7)
Study: 20655712
Drug: Dendrobium candidum
Normalized name: Geotrichum candidum
DrugBank: Geotrichum candidum (DB10699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendrobium candidum extract (DCEL) administered orally for 1 week
Study: 19450062
Drug: Solifenacin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (5 mg/day)
Study: 19450062
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER (4 mg/day)
Study: 12740260
Drug: Acetazolamide, 250
Normalized name: AcetaZOLAMIDE, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide, 250 mg bid
Study: 12740260
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA), 30 mg bid
Study: 10850938
Drug: Delayed enteral
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed enteral feeding with immune-enhancing diet (Impact with fiber) administered after gastric ileus resolved
Study: 27436632
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral and implant)
Study: 24606117
Drug: Sublingual asenapine
Normalized name: asenapine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual asenapine 10 mg
Study: 21960182
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of alcohol (0.65 g/kg)
Study: 18801887
Drug: Adiponectin concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adiponectin concentrations (highest quintile > 9.8 microg/mL)
Study: 16207605
Drug: Sustained-release nitrendipine
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release nitrendipine microspheres
Study: 16207605
Drug: Domestic commercial
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic commercial nitrendipine tablets
Study: 16207605
Drug: Baypress nitrendipine
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baypress nitrendipine tablets
Study: 12648592
Drug: Complete surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete surgical staging including bilateral salpingo‐oophorectomy, hysterectomy, omentectomy, and pelvic and para‐aortic lymphadenectomy, followed by paclitaxel and carboplatin chemotherapy
Study: 12648592
Drug: Cisplatin‐based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin‐based chemotherapy following bilateral salpingo‐oophorectomy, hysterectomy, and omentectomy without lymphadenectomy
Study: 11872915
Drug: Emergent use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergent use of anticoagulants
Study: 11872915
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin or other rapidly acting anticoagulants
Study: 7648234
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg nocte
Study: 7648234
Drug: Bezafibrate Slow
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate Slow Release (SR) 400 mg mane
Study: 7648234
Drug: Combined bezafibrate
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined bezafibrate and simvastatin therapy
Study: 31024653
Drug: Flipped classroom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flipped classroom curriculum with MKSAP readings and weekly case discussions
Study: 21769617
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of levobupivacaine twice a day postoperatively via preperitoneal catheter
Study: 16522909
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 0 mg.kg(‐1).d(‐1)
Study: 16522909
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 5 mg.kg(‐1).d(‐1)
Study: 16522909
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 10 mg.kg(‐1).d(‐1)
Study: 16522909
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 15 mg.kg(‐1).d(‐1)
Study: 16522909
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 25 mg.kg(‐1).d(‐1)
Study: 16522909
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 35 mg.kg(‐1).d(‐1)
Study: 23884718
Drug: 125 mL/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mL/h intravenously with limited oral intake
Study: 23884718
Drug: 250 mL/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL/h intravenously with limited oral intake
Study: 23884718
Drug: 25 mL/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL/h intravenously with ad libitum oral intake of clear liquids
Study: 19524265
Drug: Gastrografin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrografin (100 mL administered through a nasogastric tube)
Study: 16316567
Drug: Ferrous L-threonate
Normalized name: magnesium L-threonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous L-threonate plus placebo ferrous succinate
Study: 16316567
Drug: Ferrous succinate
Normalized name: Ferrous succinate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous succinate plus placebo ferrous L-threonate
Study: 12032434
Drug: 1-week triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week triple therapy (proton pump inhibitor, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily)
Study: 12032434
Drug: 10-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day triple therapy (proton pump inhibitor, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily)
Study: 12032434
Drug: 14-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day triple therapy (proton pump inhibitor, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily)
Study: 10472211
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution 25 ml kg‐1 infused over 15 min
Study: 10472211
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution 25 ml kg‐1 infused over 30 min
Study: 10472211
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution 25 ml kg‐1 infused over 15 min and 30 min
Study: 30384438
Drug: AboBoNT‐A (Dysport)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AboBoNT‐A (Dysport) injections (400 U) into the adductor muscles
Study: 22267183
Drug: Fluoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine treatment (8 weeks)
Study: 21152458
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (clear liquid diet and 4 L of bowel preparation without additional education)
Study: 11910715
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution (ORS) ad libitum (AL group)
Study: 11910715
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution (ORS) in fractionated doses (FD group)
Study: 1097866
Drug: Soya bean
Normalized name: Soya bean oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya bean milk (150 ml second-hourly from 7 a.m. to 11 p.m. daily for two weeks)
Study: 1097866
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no soya bean milk therapy)
Study: 31287135
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of medications during pregnancy
Study: 22084157
Drug: Intraocular lens
Normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraocular lens implant
Study: 10438343
Drug: Intravenous zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zanamivir (600 mg 2x/day for 5 days)
Study: 7006273
Drug: Norephedrine in
Normalized name: Norephedrine
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norephedrine in combination with oestradiol
Study: 30988147
Drug: Double-lactam combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-lactam combination therapy (DBL)
Study: 23503651
Drug: Poor oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor oral hygiene (brushing teeth less than daily)
Study: 21679925
Drug: Transdiagnostic internet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic internet cognitive behavioral therapy (iCBT) program consisting of online educational lessons, homework assignments, weekly contact from a clinical psychologist, access to an online forum, and automated emails.
Study: 16404361
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg m(‐2) (day 1) (arm A)
Study: 16404361
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg m(‐2) (day 8) and gemcitabine 1250 mg m(‐2) (days 1,8) (arm B)
Study: 16404361
Drug: Docetaxel 25
Normalized name: docetaxel 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 25 mg m(‐2) and gemcitabine 800 mg m(‐2) (both given weekly (days 1,8,15)) (arm C)
Study: 16404361
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 7 followed by docetaxel-based therapy
Study: 7793191
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Atracurium and Vecuronium (cAV)
Study: 31508730
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (2 hours)
Study: 28459941
Drug: iddEPC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: iddEPC regimen (E 150 mg/m2, P 225 mg/m2, C 2500 mg/m2, reduced to 2000 mg/m2 after 1200 patients) q2w i.v.
Study: 28459941
Drug: ddEC-PwX regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ddEC-PwX regimen (E 112.5 mg/m2 + C 600 mg/m2 i.v. q2w for 4 cycles, followed by Pw 67.5 mg/m2 i.v. q8d for 10 weeks + X 2000 mg/m2 p.o. days 1-14, q22 for 4 cycles)
Study: 24355670
Drug: Daily Challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Challenge (multimodal e-mail, web, and mobile-based intervention)
Study: 24355670
Drug: Traditional weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Traditional weekly health newsletter (control)